

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 April 2025 (24.04.2025)



(10) International Publication Number
WO 2025/085854 A1

(51) International Patent Classification:

A61K 31/00 (2006.01) A61P 37/06 (2006.01)
A61K 39/395 (2006.01) C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2024/052123

(22) International Filing Date:

18 October 2024 (18.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/591,736 19 October 2023 (19.10.2023) US

(71) Applicant: **ELECTRA THERAPEUTICS, INC.**
[US/US]; 201 Haskins Way, 5th Floor, South San Francisco,
California 94080 (US).

(72) Inventors: **DAO, Kim-Hien T.**; 4315 SW 58th Avenue,
Portland, Oregon 97221 (US). **PARRY, Graham C.**; 428
Timberhead Lane, Foster City, California 94404 (US). **PA-
TOU, Gary**; 26353 Esperanza Drive, Los Altos Hills, Cal-
ifornia 94022 (US).

(74) Agent: **DURON, David I.** et al.; Cooley LLP, 1299 Penn-
sylvania Ave., Suite 700, Washington, District of Columbia
20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

(54) Title: SIRP ANTIBODIES FOR TREATMENT OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS




FIG. 1A

(57) Abstract: Provided herein are clinically relevant parameters for the use of SIRP antibodies, for the treatment of hemophagocytic lymphohistiocytosis (HLH).

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*